- Question from Linda: Can you talk about the results from the Avastin/Taxotere trial? What does it mean for metastatic patients?
- Answers - Carol Kaplan The data presented at ASCO this year on docetaxel (brand name: Taxotere) and bevacizumab (brand name: Avastin) reveal that the addition of bevacizumab to docetaxel therapy yields greater efficacy. However, when compared to the paclitaxel (brand name: Taxol) and bevacizumab trial results, it seems that the docetaxel regimen comes with greater toxicity. For this reason, I personally at this time would choose to use paclitaxel with bevacizumab.
The Ask-the-Expert Online Conference called Updates From the 2008 ASCO Annual Meeting featured Generosa Grana, M.D., F.A.C.P. and Carol Kaplan, M.D. answering your questions about the latest research advances on screening, treatment, side effects, and more.
Editor's Note: This conference took place in June 2008.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.